Nanomaterials in the Context of Type 2 Immune Responses—Fears and Potentials
Open Access
- 25 April 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 471
Abstract
Preface The type 2 immune response is an adaptive immune program involved in defense against parasites, detoxification and wound healing, but is predominantly known for its pathophysiological effects, manifesting as allergic disease. Engineered nanoparticles are non-self entities that, to our knowledge, do not stimulate detrimental type 2 responses directly, but have the potential to modulate ongoing reactions in various ways, including the delivery of substances aiming at providing a therapeutic benefit. We review here the state of knowledge concerning the interaction of nanoparticles with type 2 immune responses and highlight their potential as a multifunctional platform for therapeutic intervention.Keywords
Funding Information
- Austrian Science Fund (W1213)
- Seventh Framework Programme (263147)
This publication has 185 references indexed in Scilit:
- Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: A novel tool for specific immunotherapyJournal of Controlled Release, 2013
- Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded SafetyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1βProceedings of the National Academy of Sciences, 2010
- Sensing the outside world: TSLP regulates barrier immunityNature Immunology, 2010
- Functional Interaction of Common Allergens and a C-type Lectin Receptor, Dendritic Cell-specific ICAM3-grabbing Non-integrin (DC-SIGN), on Human Dendritic CellsJournal of Biological Chemistry, 2010
- [Gd@C82(OH)22]n Nanoparticles Induce Dendritic Cell Maturation and Activate Th1 Immune ResponsesACS Nano, 2010
- Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in miceNature Nanotechnology, 2009
- Mechanism of action of clinically approved adjuvantsCurrent Opinion in Immunology, 2009
- Allergenicity resulting from functional mimicry of a Toll-like receptor complex proteinNature, 2008
- Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapyClinical and Experimental Immunology, 2008